310 related articles for article (PubMed ID: 19729086)
61. Safety and immunogenicity of a 30-valent M protein-based group a streptococcal vaccine in healthy adult volunteers: A randomized, controlled phase I study.
Pastural É; McNeil SA; MacKinnon-Cameron D; Ye L; Langley JM; Stewart R; Martin LH; Hurley GJ; Salehi S; Penfound TA; Halperin S; Dale JB
Vaccine; 2020 Feb; 38(6):1384-1392. PubMed ID: 31843270
[TBL] [Abstract][Full Text] [Related]
62. Fusion protein Ag85B-MPT64(190-198)-Mtb8.4 has higher immunogenicity than Ag85B with capacity to boost BCG-primed immunity against Mycobacterium tuberculosis in mice.
Luo Y; Wang B; Hu L; Yu H; Da Z; Jiang W; Song N; Qie Y; Wang H; Tang Z; Xian Q; Zhang Y; Zhu B
Vaccine; 2009 Oct; 27(44):6179-85. PubMed ID: 19712772
[TBL] [Abstract][Full Text] [Related]
63. Preclinical immunogenicity and safety of a Group A streptococcal M protein-based vaccine candidate.
Batzloff MR; Fane A; Gorton D; Pandey M; Rivera-Hernandez T; Calcutt A; Yeung G; Hartas J; Johnson L; Rush CM; McCarthy J; Ketheesan N; Good MF
Hum Vaccin Immunother; 2016 Dec; 12(12):3089-3096. PubMed ID: 27541593
[TBL] [Abstract][Full Text] [Related]
64. Pathogenesis of group A streptococci in mice and efficacy of locally administered streptococcal vaccines.
Bronze MS; McKinsey DS; Beachey EH; Dale JB
Trans Assoc Am Physicians; 1988; 101():88-92. PubMed ID: 3077732
[No Abstract] [Full Text] [Related]
65. Domains of group A streptococcal M protein that confer resistance to phagocytosis, opsonization and protection: implications for vaccine development.
McArthur JD; Walker MJ
Mol Microbiol; 2006 Jan; 59(1):1-4. PubMed ID: 16359313
[TBL] [Abstract][Full Text] [Related]
66. Strategic development of the conserved region of the M protein and other candidates as vaccines to prevent infection with group A streptococci.
Good MF; Pandey M; Batzloff MR; Tyrrell GJ
Expert Rev Vaccines; 2015; 14(11):1459-70. PubMed ID: 26485214
[TBL] [Abstract][Full Text] [Related]
67. Predicted Coverage and Immuno-Safety of a Recombinant C-Repeat Region Based Streptococcus pyogenes Vaccine Candidate.
McNeilly C; Cosh S; Vu T; Nichols J; Henningham A; Hofmann A; Fane A; Smeesters PR; Rush CM; Hafner LM; Ketheesan N; Sriprakash KS; McMillan DJ
PLoS One; 2016; 11(6):e0156639. PubMed ID: 27310707
[TBL] [Abstract][Full Text] [Related]
68. Identification and characterization of immunodominant B-cell epitope of the C-terminus of protective antigen of Bacillus anthracis.
Kaur M; Chug H; Singh H; Chandra S; Mishra M; Sharma M; Bhatnagar R
Mol Immunol; 2009 Jun; 46(10):2107-15. PubMed ID: 19356802
[TBL] [Abstract][Full Text] [Related]
69. Intranasal vaccination with SfbI or M protein-derived peptides conjugated to diphtheria toxoid confers protective immunity against a lethal challenge with Streptococcus pyogenes.
Schulze K; Olive C; Ebensen T; Guzmán CA
Vaccine; 2006 Aug; 24(35-36):6088-95. PubMed ID: 16828529
[TBL] [Abstract][Full Text] [Related]
70. Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: phase 1 trial.
Kotloff KL; Corretti M; Palmer K; Campbell JD; Reddish MA; Hu MC; Wasserman SS; Dale JB
JAMA; 2004 Aug; 292(6):709-15. PubMed ID: 15304468
[TBL] [Abstract][Full Text] [Related]
71. Host-pathogen interactions in Streptococcus pyogenes infections, with special reference to puerperal fever and a comment on vaccine development.
Areschoug T; Carlsson F; Stålhammar-Carlemalm M; Lindahl G
Vaccine; 2004 Dec; 22 Suppl 1():S9-S14. PubMed ID: 15576204
[TBL] [Abstract][Full Text] [Related]
72. Vaccine potential of recombinant Ornithobacterium rhinotracheale antigens.
Schuijffel DF; Van Empel PC; Segers RP; Van Putten JP; Nuijten PJ
Vaccine; 2006 Mar; 24(11):1858-67. PubMed ID: 16318896
[TBL] [Abstract][Full Text] [Related]
73. Biological consequences of antigen and cytokine co-expression by recombinant Streptococcus gordonii vaccine vectors.
Byrd CM; Bolken TC; Jones KF; Warren TK; Vella AT; McDonald J; King D; Blackwood Z; Hruby DE
Vaccine; 2002 May; 20(17-18):2197-205. PubMed ID: 12009273
[TBL] [Abstract][Full Text] [Related]
74. Vaccination against the M protein of Streptococcus pyogenes prevents death after influenza virus: S. pyogenes super-infection.
Klonoski JM; Hurtig HR; Juber BA; Schuneman MJ; Bickett TE; Svendsen JM; Burum B; Penfound TA; Sereda G; Dale JB; Chaussee MS; Huber VC
Vaccine; 2014 Sep; 32(40):5241-9. PubMed ID: 25077423
[TBL] [Abstract][Full Text] [Related]
75. Immunogencity of HSA-L7/L12 (Brucella abortus ribosomal protein) in an animal model.
Pakzad I; Rezaee A; Rasaee MJ; Tabbaraee B; Delpisheh A
Iran J Immunol; 2009 Mar; 6(1):12-21. PubMed ID: 19293473
[TBL] [Abstract][Full Text] [Related]
76. Development of a recombinant fusion protein vaccine formulation to protect against Streptococcus pyogenes.
Morefield G; Touhey G; Lu F; Dunham A; HogenEsch H
Vaccine; 2014 Jun; 32(30):3810-5. PubMed ID: 24837509
[TBL] [Abstract][Full Text] [Related]
77. Binding of human plasma proteins to Streptococcus pyogenes M protein determines the location of opsonic and non-opsonic epitopes.
Sandin C; Carlsson F; Lindahl G
Mol Microbiol; 2006 Jan; 59(1):20-30. PubMed ID: 16359315
[TBL] [Abstract][Full Text] [Related]
78. New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci.
Dale JB; Penfound TA; Chiang EY; Walton WJ
Vaccine; 2011 Oct; 29(46):8175-8. PubMed ID: 21920403
[TBL] [Abstract][Full Text] [Related]
79. Correlates of Protection for M Protein-Based Vaccines against Group A Streptococcus.
Tsoi SK; Smeesters PR; Frost HR; Licciardi P; Steer AC
J Immunol Res; 2015; 2015():167089. PubMed ID: 26101780
[TBL] [Abstract][Full Text] [Related]
80. Physicochemical characterisation, immunogenicity and protective efficacy of a lead streptococcal vaccine: progress towards Phase I trial.
Pandey M; Powell J; Calcutt A; Zaman M; Phillips ZN; Ho MF; Batzloff MR; Good MF
Sci Rep; 2017 Oct; 7(1):13786. PubMed ID: 29062085
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
